Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: analysis by the centerline method with correction for area at risk.

Angiographic frame counts 90 minutes after streptokinase predict left ventricular function at 48 hours following myocardial infarction. Heart (1999) 0.79

Does primary stenting preserve cardiac function in myocardial infarction? A case-control study. NORTH-981 investigators. Network of revascularisation therapy in Hokkaido. Heart (2000) 0.75

Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation (1987) 7.14

Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med (1999) 6.93

A new coronary prognostic index. Lancet (1969) 6.37

Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53

Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19

Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med (1987) 4.08

ADP dissociation from actomyosin subfragment 1 is sufficiently slow to limit the unloaded shortening velocity in vertebrate muscle. Proc Natl Acad Sci U S A (1985) 4.01

Energetics and mechanism of actomyosin adenosine triphosphatase. Biochemistry (1976) 3.97

Coronary prognostic index for predicting survival after recovery from acute myocardial infarction. Lancet (1970) 3.58

Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand. N Z Med J (1993) 3.18

Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet (1999) 2.63

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ (1996) 2.62

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53

Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation (1993) 2.42

Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction. Circulation (1975) 2.38

Prognosis after myocardial infarction. Six-year follow-up. Br Heart J (1974) 2.17

Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1995) 2.12

One-year survival following early revascularization for cardiogenic shock. JAMA (2001) 2.10

Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation (1995) 2.08

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08

One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03

Special instrumentation and techniques for kinetic studies of contractile systems. Methods Enzymol (1982) 2.02

Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation (1994) 2.02

Comparing health expenditure. N Z Med J (1996) 1.92

Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med (1989) 1.91

Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Eur Heart J (1995) 1.90

Trial of propranolol in acute myocardial infarction. Br Med J (1968) 1.89

Mortality in a coronary-care unit analysed by a new coronary prognostic index. Lancet (1969) 1.87

Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87

Kinetics of the interaction between actin, ADP, and cardiac myosin-S1. J Biol Chem (1984) 1.86

Heart block in posterior and anterior myocardial infarction. Br Heart J (1969) 1.86

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83

Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med (1997) 1.83

Waiting times and prioritization for coronary artery bypass surgery in New Zealand. Heart (1999) 1.81

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 1.78

Long-term survival and valve-related complications in young women with cardiac valve replacements. Circulation (1999) 1.77

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care (1997) 1.76

Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J (2000) 1.73

Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol (1997) 1.72

Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy. Identification of a causal agent for impaired myocardial function. Circulation (1992) 1.70

Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation (1978) 1.68

Plasma propranolol concentration in patients with angina and acute myocardial infarction. Clin Exp Pharmacol Physiol (1976) 1.68

Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol (2000) 1.66

Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial. Heart (2008) 1.64

Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. J Am Coll Cardiol (1990) 1.64

Characterization of brain microtubule proteins prepared by selective removal of mitochondrial and synaptosomal components. J Biol Chem (1979) 1.59

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1999) 1.59

Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet (2000) 1.56

Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J (1990) 1.54

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (2008) 1.54

New Q waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction. Eur Heart J (2000) 1.51

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J (2002) 1.50

Clinical trials and clinical practice. Lancet (1993) 1.49

Serum troponins T and I after elective cardioversion. Eur Heart J (2000) 1.45

Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J (2003) 1.42

Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA (1996) 1.41

A direct threat to research in public hospitals. N Z Med J (1995) 1.39

Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. N Z Med J (1990) 1.39

New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J (2000) 1.39

Hospital mortality in acute myocardial infarction. Br Med J (1968) 1.39

Cost of coronary heart disease in New Zealand. N Z Med J (1993) 1.38

Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. Eur Heart J (2002) 1.38

Resuscitation equipment and general practitioners. Br J Gen Pract (1997) 1.38

Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol (1993) 1.33

Effects of verapamil on infarct size following experimental coronary occlusion. Cardiovasc Res (1975) 1.32

Protective effect of propranolol in threatened myocardial infarction. Lancet (1978) 1.32

Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation (2000) 1.31

Unique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium. J Leukoc Biol (1997) 1.31

Temperature and ligand dependence of conformation and helical order in myosin filaments. Biochemistry (2003) 1.27

Long term prognosis following treatment in coronary-care unit. Aust N Z J Med (1973) 1.22

Failure of ST segment elevation to predict severity of acute myocardial infarction. Br Heart J (1976) 1.21

End-systolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular function. Circulation (1994) 1.20

Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol (1993) 1.20

Effects of mutations in the gamma-phosphate binding site of myosin on its motor function. J Biol Chem (1998) 1.19

Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation (1994) 1.19

Prognosis in unstable angina. Br Heart J (1976) 1.18

Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death. Am J Cardiol (1984) 1.18

Conduction disturbances due to anteroseptal myocardial infarction and their treatment by endocardial pacing. Am Heart J (1972) 1.18

Prognosis after myocardial infarction: results of 15 year follow up. Br Med J (Clin Res Ed) (1984) 1.17

Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation (1996) 1.16

Coronary surgery after recurrent myocardial infarction: progress of a trial comparing surgical with nonsurgical management for asymptomatic patients with advanced coronary disease. Circulation (1981) 1.15

End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Circulation (1997) 1.15

Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.15

Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. Am Heart J (1999) 1.12

Different mechanisms for Ca2+ dissociation from complexes of calmodulin with nitric oxide synthase or myosin light chain kinase. J Biol Chem (1996) 1.11

Alprenolol in acute myocardial infarction: Double-blind trial. N Z Med J (1970) 1.11

Observation of transient disorder during myosin subfragment-1 binding to actin by stopped-flow fluorescence and millisecond time resolution electron cryomicroscopy: evidence that the start of the crossbridge power stroke in muscle has variable geometry. Proc Natl Acad Sci U S A (1999) 1.11

Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation (1998) 1.08

Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Stroke (1998) 1.08

Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation (2001) 1.07

Acute coronary care. N Z Med J (1968) 1.06

Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction. Br Heart J (1993) 1.06

The results of surgical treatment of left ventricular aneurysms. An assessment of the risk factors affecting early and late mortality. J Thorac Cardiovasc Surg (1984) 1.06

Dithering over the treatment of diabetics with acute myocardial infarction. Eur Heart J (2000) 1.06

Postsystolic shortening of acutely ischemic canine myocardium predicts early and late recovery of function after coronary artery reperfusion. Circulation (1988) 1.06